Please wait while the transcript is being prepared...
0:00
Hi, this is Victor Appay speaking from
The National Institute of Health and Medical Research in France.
In the second part of my talk,
I will concentrate more on the relationship of
T cell priming in the context of tumour micro-environment,
and its application in the context of cancer immunotherapy and aging.
0:20
Now in this fourth part,
I will discuss about T cell priming in the context of the tumour micro-environment.
0:29
It has been shown that upon injection in mice,
naive cells can infiltrate directly tumours,
and this has been associated with an improved survival of the mice bearing the tumours.
0:45
Interestingly, increasing evidence support that tumours can support
the infiltration, activation, and effector differentiation of naive CD8 T cells.
Indeed, the adoptive transfer of naive tumour-specific CD8 T cells,
into tumour-bearing mice, has been associated with
the accumulation of activated CD8 T cells in the tumours,
the acquisition of effector function,
and the presentation of antigen to
these cells by cross-presenting antigen presenting cells.
Also, the recruitment of naive T cell within tumours has been shown to be
favoured by the presence of high endothelial venules or HEVs.
HEVs have been identified in a range of human tumours,
and usually their presence has been associated with
the observation of CD8 T effector cells, B cells,
Th1 cells within the tumours,
and organised into so-called tertiary lymphoid structures or TLS.
